Disease Overview：Acute Lymphoblastic Leukemia（ALL）
Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy characterized by the uncontrolled proliferation of immature B- or T-lymphoid precursors in the bone marrow, peripheral blood, and extramedullary sites. It accounts for approximately 80% of childhood leukemias and a smaller but clinically significant proportion of adult cases. Diagnosis relies on comprehensive evaluation including peripheral blood smear, bone marrow aspiration and biopsy, flow cytometry, cytogenetic analysis (e.g., detection of Philadelphia chromosome, ETV6-RUNX1, KMT2A rearrangements), and molecular profiling. Risk stratification guides therapy intensity, which typically involves multi-phase chemotherapy—induction, consolidation, intensification, and maintenance—alongside central nervous system prophylaxis. For high-risk or relapsed/refractory disease, allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative option. Outcomes vary significantly by age, genetic profile, and early treatment response; pediatric 5-year overall survival exceeds 90%, while adult rates range from 40–70%, underscoring the importance of timely, precision-based care.
China offers compelling advantages for ALL management: leading hematology centers—such as Peking University People’s Hospital and Shanghai Ruijin Hospital—boast internationally trained specialists with extensive experience in risk-adapted protocols and minimal residual disease (MRD)-guided therapy. Advanced infrastructure includes next-generation sequencing platforms, digital flow cytometry, and CAR-T cell manufacturing facilities approved by China’s NMPA. Published outcomes demonstrate comparable or superior remission rates and transplant survival versus Western benchmarks, particularly in adolescent and young adult cohorts. Crucially, treatment costs—including HSCT and novel immunotherapies—are typically 40–60% lower than in the US or Western Europe, without compromising clinical rigor or regulatory compliance. As a dedicated medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with certified hematologists, verifying hospital accreditation and physician credentials, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and medical translation to post-treatment follow-up coordination and accommodation logistics.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Acute Lymphoblastic Leukemia (ALL)
Non-Surgical/Medical Therapy (First-Line & Maintenance)
*Eligibility*: Newly diagnosed ALL (Ph− or Ph+), relapsed/refractory cases, pediatric and adult patients fit for chemotherapy.
- •Induction Chemotherapy (4–6 weeks)
- *Supportive care*: IV antibiotics ($95), growth factor (G-CSF, $180), transfusions (RBC $75/unit, platelets $110/unit) - *Monitoring labs*: CBC daily ($8), peripheral smear ($15), bone marrow aspirate/biopsy ($210), flow cytometry ($190), PCR for minimal residual disease (MRD) ($240) - Total induction tier: $1,455–$2,100
- •Consolidation/Intensification (8–12 weeks)
- CNS prophylaxis lumbar puncture ($65) - Total consolidation tier: $635–$920
- •Maintenance Therapy (2–3 years)
- Annual cost: $2,800–$3,400
Procedural/Interventional Options
*Eligibility*: High-risk/relapsed/refractory ALL, MRD-positive after induction, Ph+ ALL, or candidates for curative intent.
- •Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- *Procedure*: Conditioning (fludarabine/busulfan, $1,250), stem cell infusion ($480), inpatient stay (30 days avg, $1,950) - *Post-transplant*: GVHD management (tacrolimus $210/month × 6 mo = $1,260), chimerism testing ($140 × 4 = $560), infection surveillance ($380) - Total allo-HSCT package: $6,210–$7,850
- •CAR-T Cell Therapy (for R/R B-ALL)
- *Fees*: Leukapheresis ($420), manufacturing ($14,800), lymphodepletion chemo ($360), inpatient monitoring (14 days, $1,120), cytokine release syndrome management ($1,850) - Total CAR-T package: $18,610
Special/Complex Condition Management
- •Ph+ ALL with TKI resistance: Ponatinib ($2,100/month × 6 mo = $12,600) + blinatumomab ($3,400/dose × 4 cycles = $13,600) → $26,200
- •CNS involvement: Intrathecal triple therapy (methotrexate/cytarabine/hydrocortisone, $45/injection × 12 = $540) + cranial irradiation ($1,850) → $2,390
Quick Selection Guide
- •Children (<15 y, standard-risk): Induction + consolidation + 2-year maintenance → $5,200–$6,800
- •Adults (15–60 y, high-risk): Intensified chemo + allo-HSCT → $6,200–$7,900
- •Elderly (>60 y, comorbidities): Reduced-intensity chemo + targeted agents (e.g., dasatinib $1,400/mo × 6 = $8,400) → $8,400–$10,200
- •R/R ALL (any age): CAR-T preferred if CD19+, otherwise allo-HSCT → $18,600 vs. $7,100
- •Budget-constrained (<$5,000): Generic chemo regimens (vincristine/daunorubicin/prednisone only) + supportive care → $3,900–$4,700
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Acute Lymphoblastic Leukemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Acute Lymphoblastic Leukemia treatment with China top medical destinations:
